Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02450331 · ClinicalTrials.gov registry record · Phase 3
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Terminated
- Registry status
- Phase 3
- Development phase
- 809
- Enrollment target
NCT02450331 is a Phase 3 study that was terminated before completion, run by Hoffmann-La Roche. The registered enrollment target is 809 participants.
The verdict
NCT02450331, a Phase 3 study, was terminated before completion, sponsored by Hoffmann-La Roche.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 809 participants
- Enrollment target
Study Summary
This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by a 1:1 ratio into atezolizumab group or control group.
Interventions
- DRUG Atezolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 809 participants |
| Start Date | 2015-10-05 |
| Est. Completion | 2022-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02450331
The ClinicalTrials.gov registry entry for NCT02450331 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 809 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atezolizumab is the first listed.
NCT02450331 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02450331 about?
NCT02450331 is a clinical study titled "A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection". This Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive UC who are at high risk for recurrence following resection. Eligible participants were randomized by...
What is the current status of trial NCT02450331?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 809 participants. The study started on 2015-10-05. Estimated completion is 2022-06-14.
What interventions are being tested in trial NCT02450331?
The interventions under investigation include: Atezolizumab (DRUG).
Who is sponsoring clinical trial NCT02450331?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.